Table 2.
Comparison of Baseline Characteristics Among White and Black Veterans in Observational Cohort Analysis (N = 1270)
| Factor | White | Black | P Value* |
|---|---|---|---|
| Age (median in years) | 72.2 | 69.1 | <.001 |
| N (%) | N (%) | ||
| First-degree relative: | .52 | ||
| No | 1058 (93.6) | 132 (95.0) | |
| Yes | 73 (6.5) | 7 (5.0) | |
| Comorbidity: | .37 | ||
| 0 | 302 (26.7) | 42 (30.2) | |
| 1 | 333 (29.4) | 42 (30.2) | |
| 2 | 248 (21.9) | 26 (18.7) | |
| ≥3 | 248 (21.9) | 29 (20.9) | |
| Anatomic stage: | .007 | ||
| I or II | 1014 (89.7) | 115 (82.7) | |
| III | 52 (4.6) | 8 (5.8) | |
| IV | 65 (5.8) | 16 (11.5) | |
| Histologic grade: | .27 | ||
| well differentiated | 264 (23.4) | 34 (24.5) | |
| moderately differentiated | 686 (60.8) | 73 (52.5) | |
| poorly differentiated | 178 (15.8) | 32 (23.0) | |
| Baseline PSA:† | .001 | ||
| 0–4 | 162 (14.8) | 20 (14.5) | |
| 4–10 | 402 (36.7) | 34 (24.6) | |
| 10–20 | 268 (24.5) | 25 (18.1) | |
| 20+ | 264 (24.1) | 59 (42.8) | |
| D’Amico score:‡ | .001 | ||
| Low | 375 (30.2) | 32 (2.6) | |
| Moderate | 348 (27.9) | 38 (3.0) | |
| High | 387 (31.0) | 69 (5.5) | |
| Treatment: | .04 | ||
| Watchful waiting/none | 337 (29.8) | 30 (21.6) | |
| Prostatectomy | 210 (18.6) | 30 (21.6) | |
| Beams/“seeds” | 386 (34.1) | 45 (32.4) | |
| Neoadjuvant only | 198 (17.5) | 34 (24.5) | |
| Prostate cancer mortality: | .58 | ||
| Yes | 175 (15.5%) | 24 (17.3%) | |
| No | 956 (84.5%) | 115 (82.7%) |
PSA = prostate-specific antigen.
*
P values determined, as appropriate, by chi-square test, chi-square test for linear trend, or Wilcoxon rank-sum test.
†
N = 1234 after accounting for missing values from 36 patients.
‡
N = 1249 after accounting for missing values from 21 patients; the D’Amico score17 was used as a composite variable representing prostate cancer prognosis.